| Date | Title | Description |
| 27.03.2026 | 'We need to put some bad ideas to bed': Inside Incubate's battles for biotech on Capitol Hill | Incubate Founder and Executive Director John Stanford spent a busy day on Capitol Hill this week making the case that the success of the domestic biotech industry is an issue of national security, health care access and economic competitive... |
| 26.03.2026 | OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline | Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million.
OrbiMed, which has backed Pinnacle since its in... |
| 19.03.2026 | Moon Rabbit Appoints Loren Levinson EVP, Executive Strategy Director | Leadership addition expands agency's strategy capabilities amid continued growth
NEW YORK, March 19, 2026 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and healthcare, today announced t... |
| 17.03.2026 | R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment | R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class therapy for chronic kidney disease (CKD) patients on dialysis with high phosphate levels.
The funding was co-led by Ab... |
| 12.03.2026 | Novo Holdings sees assets shrink by a 3rd in wake of Novo Nordisk's nosediving share price | Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price.
The Copenhagen-based firm, which is the controlling shareholder of Novo Nordisk, oversaw total assets of 694 billion D... |
| 10.03.2026 | Breakout Ventures launches $114M AI-focused fund | San Francisco venture capital firm Breakout Ventures announced the close of a $114 million fund to support founder-led companies working at the nexus of science and artificial intelligence.
Breakout’s Fund III brings together new investors ... |
| 05.03.2026 | VC firm to open 30K-square-foot biotech incubator in Salt Lake City | Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while also establishing a venture fund to support early-stage life sciences and biotech companies.
The expansion is part of... |
| 18.02.2026 | Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody | A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences has catapulted out of stealth with $175 million and designs for a 2027 clinical debut.
The newly disclo... |
| 16.02.2026 | Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook | Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms and is expected to display a “continued,... |
| 12.02.2026 | European VCs join forces to boost flagging biotech investment in the region | Heavyweight European venture capital firms like Novo Holdings and Sofinnova Partners have joined together to make the case for more urgently needed funding in the continent's biotech ecosystem.
The European Life Sciences Coalition (ELSC), w... |
| 03.02.2026 | OS Therapies Initiates FDA BLA Filing for OST-HER2 to Prevent or Delay Recurrent Pulmonary Metastatic Osteosarcoma | At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous osteosarcoma in canines
Company remains ... |
| 22.01.2026 | Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug | In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.
Shanghai-headquartered Corxel licens... |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 09.01.2026 | AirNexis takes flight with $200M, links up with China pharma for COPD asset in $955M biobucks deal | AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a Chinese pharma that aims to treat lung disease.
Founded by investment firm Frazier Life Sciences, new biotech AirNexis has connected with Haisco Phar... |
| 08.01.2026 | Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug | Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug.
The funds come from a smorgasbord of existin... |
| 08.01.2026 | Innovation isn't enough: Biopharma needs urgent reinvention, PwC says | Attempting to scry the future of the pharmaceutical industry, professional services juggernaut PwC has laid out lofty ambitions for what it believes drugmakers could achieve by 2035—as well as the steps those companies should take in 2026 t... |
| 18.12.2025 | Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A | A new mental health-driven biotech has arrived in Syremis Therapeutics. Co-founded by the mind behind Karuna Therapeutics and its novel schizophrenia treatment Cobenfy, the company has officially launched its mission to advance innovative t... |
| 01.12.2025 | Protego plans pivotal trial for AL amyloidosis prospect with $130M series B | Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new $130 million series B fundraise.
The oversubscribed funding round, led by Novartis Venture Fund and Forbion, picke... |
| 01.12.2025 | EU teams up with Angelini to funnel €150M to European health startups | The EU has launched a new funding initiative to support healthcare startups across the continent. The EU’s investment arm, the European Investment Bank (EIB), is teaming up with Italian conglomerate Angelini Industries to funnel 150 million... |
| 24.11.2025 | 'People are getting used to it': Global uncertainties can't dampen upbeat Jefferies conference | The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market volatility, tariffs and a slowly dethawing IPO market continued to cast long shadows.
Still, no matter who Fierce cou... |
| 15.10.2025 | Arthrosi Secures $153 Million to Accelerate Gout Treatment | Arthrosi Therapeutics recently closed a significant $153 million Series E funding round. This vital capital directly supports late-stage clinical development of pozdeutinurad, a promising next-generation URAT1 inhibitor. The San Diego-based... |
| 15.10.2025 | Pelage Pharma raises $120M series B to untangle roots of hair loss with regenerative med | The latest strand in Pelage Pharmaceuticals’ growing funds comes from a $120 million series B fundraising round that the biotech plans to apply to its regenerative hair loss treatment.
Arch Venture Partners and Google Ventures co-led the fu... |
| 09.10.2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| 08.10.2025 | Arthrosi raises $153M, fueling dash toward phase 3 gout data in 2026 | Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year.
San Diego-based Arthrosi completed enrollme... |
| 22.09.2025 | Big Pharma-backed MapLight plots IPO to advance neuro pipeline | MapLight Therapeutics has illuminated a path toward an initial public offering, filing with the Securities and Exchange Commission (SEC) on Sept. 19 to be listed on the Nasdaq under the ticker symbol "MPLT."
Should the IPO go thro... |
| 17.09.2025 | Eye disease biotech launches with $100M and sights set on Roche showdown | During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the blockbuster eye disease med Vabysmo (faricimab). Now, as the co-founder and CEO of newly launched Ollin Biosciences, Ehrlic... |
| 17.09.2025 | VC Aditum launches cardiovascular biotech, offers Mabwell up to $1B for siRNA asset | California VC firm Aditum Bio is at it again, this time partnering up with China-based Mabwell Bioscience to launch a new biotech focused on cardiovascular disease.
Aditum has paid Mabwell $12 million in upfront and near-term payments for e... |
| 09.09.2025 | Trump signs memo to crack down on direct-to-consumer pharma ads | President Donald Trump signed a memorandum that aims to crack down on direct-to-consumer prescription drug ads, in a move that stops short of an outright ban.
The Trump administration will send out around 100 cease-and-desist enforcement le... |
| 13.08.2025 | VC firm Hatteras reels in $200M across 2 funds for early-stage life sciences investments | Hatteras Venture Partners has secured over $200 million across a pair of funds that are set to benefit up-and-coming biotechs alongside medtech and healthcare companies.
The money is spread across two funds—Hatteras’ seventh venture fund an... |
| 07.08.2025 | Artbio Secures $132M to Accelerate Precision Cancer Therapies | Artbio, a pioneering radiopharmaceutical firm, locked in $132 million Series B funding. This investment drives AB001, its innovative alpha radioligand therapy for metastatic castration-resistant prostate cancer, toward Phase II clinical tri... |
| 31.07.2025 | Frazier Life Sciences raises $1.3B for latest early-stage biotech venture fund | Frazier Life Sciences has gathered an impressive $1.3 billion in capital commitments for its 12th venture fund aimed at private early-stage biotechs.
The Palo Alto-based firm said it has now raised more than $3.6 billion across five dedicat... |
| 29.07.2025 | Radiopharma-focused Artbio paints path to clinic with $132M series B | Radiopharmaceuticals-focused Artbio has drawn in a $132 million series B to push its lead prostate cancer prospect through phase 2 trials and bolster its supply chain.
The round was co-led by Sofinnova Investments and B Capital, both new in... |
| 10.07.2025 | Radiopharma biotech raises $99M series B to test copper-based diagnostic, therapeutic combo | Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical journey of its copper-based radiopharmaceutical diagnostic and therapeutic offering.
The series B round was led by a q... |
| 20.06.2025 | Syncona blames 'challenging' market for shift in biotech investment strategy | Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy away from early-stage biotechs and focusing on companies likely to offer near-term rewards.
The London-based firm’s ... |
| 18.06.2025 | Taxes, tariffs and interest rates hold key to biotech's future amid uncertain outlook: EY | Against an increasingly uncertain market backdrop, industry analysts EY said they are keeping an eye on potential pharmaceutical tariffs, tax rates and any drop in interest rates as key signposts for the sector's health.
With these variable... |
| 10.06.2025 | Questex Recognised for Content and Data-Driven Marketing Solutions | Questex, the leading information and event services company focused on the experience economy, announces it has been recognized for its impactful content and innovative data-driven marketing solutions from the Jesse H. Neal Awards, the Amer... |
| 24.05.2025 | Pharmacists stockpile most common drugs on chance of targeted Trump tariffs | Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, and middlemen — opposes most tariffs.
Slas... |
| 20.05.2025 | SV Health’s latest pharma-backed dementia fund raises $269M to invest in new therapies | A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund.
The first Dementia Discovery Fund (DDF) was launched by VC firm SV Health Investors a decade ago with the goal of deliv... |
| 16.05.2025 | The Glyphosate Gamble: Georgia's New Law and the Future of Agriculture | In a bold move, Georgia has become the second state in the U.S. to shield Bayer, the maker of Roundup, from certain cancer claims. This law, set to take effect on January 1, 2026, is a double-edged sword. It aims to protect farmers and the ... |
| 15.05.2025 | Denmark’s economy boomed on drug exports — Trump’s tariffs threat won’t be what slows it down | Denmark’s economic growth, which was driven by what economists described as an “exceptional surge” in pharmaceutical exports, is expected to weaken this year.
The looming threat of U.S. tariffs on the pharma industry won’t be much of a fact... |
| 13.05.2025 | Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug | Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare neurological disease drug through two late-stage trials.
The candidate in question is nizubaglustat, a brain-penetrant ... |
| 07.05.2025 | Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs | California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies.
The Vivo Opportunity Fund is an evergreen public fund that runs in three-year investment... |
| 18.04.2025 | 'America-first resurgence': Amid market correction, biotech nears new era, PitchBook says | Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” according to a new report from PitchBook. Companies focused on AI integration and manufacturing innovation are expected t... |
| 18.03.2025 | Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy | As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead liver-targeting gene therapy into human trials.
The series C was led by Arch Venture Partners and TCGX, with new investors ... |
| 17.03.2025 | Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic | Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management drugs.
The round was led by Blue Owl Capital, with other participants including Deep Track Capital, Ac... |
| 20.12.2024 | Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business | Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for $44 million upfront.
The Los Angeles-based ... |
| 19.12.2024 | The Shifting Sands of Pharma and Energy: Opportunities Amidst Uncertainty | In the world of finance, change is the only constant. Two sectors currently in the spotlight are pharmaceuticals and energy. Both face unique challenges and opportunities. Investors must navigate these shifting sands carefully.
Novo Nordisk... |
| 19.12.2024 | Former Seagen CEO's biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic | Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in series A funds to push forward its potential Keytruda contender.
Ottimo was born in 2020 out of a collaborat... |
| 18.12.2024 | Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. |
Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: NVO). The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. Marketed th... |
| 13.11.2024 | Keurig Dr Pepper taps new CMO to accelerate digital-first marketing | Listen to the article 3 min
This audio is auto-generated. Please let us know if you have feedback.
Keurig Dr Pepper has appointed Drew Panayiotou as CMO of U.S. refreshment beverages, effective immediately, according to a press release. The... |
| 13.11.2024 | DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution | DKSH Healthcare and Euris have launched "ConnectPlus", a complete Customer Relationship Management (CRM) and Multi-Channel Engagement (MCE) platform set to transform healthcare distribution across APAC. This data-driven, agile sol... |
| 12.11.2024 | Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech | Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two antibody-drug conjugates (ADCs).
Healthcare investor OrbiMed led the oversubscribed series D financing, with Novo Nordi... |
| 21.10.2024 | Seaport loads up $225M series B to continue Karuna veterans' voyage to clinical milestones | After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 million in series B funds to support the journey to key clinical milestones for its neuropsychiatric medicines.
Sea... |
| 15.10.2024 | New cell therapy biotech emerges with $17M, thymus-targeting therapies | Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ.
The Philadelphia biotech’s seed financing was led by Columbus Venture Partne... |
| 14.10.2024 | Fastenal and Eli Lilly: Two Titans of Industry on the Rise | In the world of stocks, two companies are making waves: Fastenal and Eli Lilly. Each stands tall in its respective field, showcasing resilience and innovation. Fastenal, a giant in inventory management, is poised to reclaim its all-time hig... |
| 13.10.2024 | Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. |
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world. It took that mantle from the long-held dominance by Johnson and Johnson (NYSE: JNJ) back in May of 2... |
| 07.10.2024 | Judo kickstarts with $100M to develop genetic medicines that strike out kidney disease | Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting the kidney.
Instructing Judo is CEO Rajiv Patni, M.D., an industry vet who most recently served as chief R&D off... |
| 31.07.2024 | A New Dawn for Alzheimer's Treatment: The Promise of GLP-1 Drugs | In the realm of Alzheimer's research, a new player has emerged, and it’s wearing the familiar coat of a diabetes medication. Liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, has shown potential in slowing cognitive decline, igniting ... |
| 30.07.2024 | Novo's Victoza Drug For Diabetes Shows Promise in Alzheimer's Treatment, But Misses Primary Goal | By Joseph Henry
Published Jul 30, 2024 9:09AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
Novo Nordisk's Victoza, a popular diabetes medication, has shown mixed results in a mi... |
| 16.07.2024 | Novo Holdings, J&J-backed Asceneuron raises $100M to take Alzheimer's asset into phase 2 | With the first wave of Alzheimer’s disease drugs reaching the market, investors continue to seek out the next big advance in this red-hot area of neuroscience R&D.
For Novo Holdings, the controlling shareholder of Novo Nordisk, this has... |
| 20.06.2024 | Biopharma dealmaking continues to rise, but M&A values hold steady: PwC | Thanks to a flurry of dealmaking across the Christmas period and into the new year, it sure feels like both biotechs and Big Pharma have picked up the pace when it comes to hunting down fresh assets. After crunching the data, PwC has come t... |
| 31.05.2024 | Moderna's RSV vaccine for older adults approved | figcaption>span]:font-sans">
Moderna's RSV shot for adults 60 and older was approved by the Food and Drug Administration on Friday, joining a growing group of vaccines protecting against the major respiratory threat.
Why it matte... |
| 03.04.2024 | Diagonal launches with $128M and a platform slanted toward agonist antibodies | Diagonal Therapeutics is taking shape, launching with $128 million and backed by the likes of BVF Partners, Atlas Venture and RA Capital to develop a pipeline of antibody agonists.
The company will use this significant financial firepower t... |
| 27.03.2024 | Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive | With the search for a partner for an approved stem cell therapy coming up short, cash-strapped Gamida Cell has accepted that the only way to remain a going concern is to allow its principal lender to acquire the company.
The agreement will ... |
| 25.03.2024 | Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome | TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating
Prader Willi syndrome is the most common genetic cause of life-threatening childhood obesity
... |
| 15.03.2024 | Health | Why COVID patients who could most benefit from Paxlovid still aren’t getting it | Arthur Allen | KFF Health News (TNS)
Evangelical minister Eddie Hyatt believes in the healing power of prayer but “also the medical approach.” So on a February evening a week before scheduled prostate surgery, he had his sore throat checked... |
| 29.02.2024 | With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules | The first signs of spring are beginning to emerge and so too are the shoots of the next biotech from drug designer J. Jean Cui, Ph.D.
BlossomHill Therapeutics has raised $100 million in a series B financing, bringing the company’s total fun... |
| 23.02.2024 | The Triangle's biotech growth has skyrocketed in the past decade | Data: CBRE; Chart: Axios Visuals
In less than a decade, the Triangle's biotech industry has more than doubled its lab space and added tens of thousands of new workers, as the region's profile among investors and companies soars.
The big pic... |
| 22.02.2024 | Frontier CEO weathers 'one of the hardest financings' of his career to close $80M series C | Frontier Medicines has just closed a $80 million fundraising, but, according to CEO Chris Varma, Ph.D., corralling the capital was, in his own words, harder than the bleakest days of the Great Recession.
“I've been either an investor or an ... |
| 21.02.2024 | It’s a mistake to assume Elon Musk is lying all the time—but his Neuralink comment needs verification | So, what to make of that Elon Musk comment earlier this week about Neuralink’s first patient seemingly recovering well and being able to control a mouse via his brain implant?
Let me start with a kind of defense of Musk: I think some people... |
| 13.02.2024 | Capitalizing on ADC frenzy, ProfoundBio attracts $112M oversubscribed series B | With Big Pharmas heading into 2024 with a renewed interest in antibody-drug conjugates (ADCs), it’s no surprise that ProfoundBio managed to assemble a who’s who of biotech investors for an oversubscribed series B round.
The likes of Lilly A... |
| 29.01.2024 | 23andMe breach targeted Chinese, Jewish populations | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. Today, we discuss how Medicaid might pay for the costly but potentially curative sickle cell gene therapi... |
| 19.01.2024 | The Senate health committee looks into its first subpoena in 40 years | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
We’re seeing some rays of hope that this ghastly biotech job market may loosen up a bit. Also, Bernie Sanders wants ... |
| 16.01.2024 | The four biotech stories you need to read this morning | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Hope you had a restful and reflective long weekend. Today, we talk a lot about regulatory policy — for flu va... |
| 09.01.2024 | JPM24, Day 2: GSK, Eli Lilly, Blueprint, SR One and more | Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2024 in San Francisco. Yesterday "Merger Monday" lived up to its name with deals for Novartis, J&J and Merck, and today, we’re also starting Tuesday with an early deal.... |
| 08.01.2024 | Biopharma M&A ripens as JPM launches | The JPMorgan Health Care Conference — the definitive launchpad for industry dealmaking — kicked off Monday.
Why it matters: As interest rates stabilize and the funding market for biotech rebounds, there will be plenty of white space in phar... |
| 08.01.2024 | JPM24 opens with ADCs the hottest ticket in San Francisco | The overall deal flow in biopharma tapered off in 2023 but the big companies sure know what they want (what they really, really want), according to a new report from J.P. Morgan.
And that’s antibody-drug conjugates, which drove a fourth-qua... |
| 29.12.2023 | There’s a less intimidating alternative to EpiPens for dangerous allergic reactions. Why won’t the FDA approve it? | My son Thomas has carried around a needle since he entered kindergarten at the age of 5. That was a big responsibility for a small child to carry an injector loaded with lifesaving epinephrine, but since he was 19 months old, he has worked ... |
| 27.12.2023 | Editor's Corner: Fierce Biotech's top 10 editor's picks for 2023 | The Fierce Biotech team has been all over the place this year: Copenhagen, Madrid, London, New York, Chicago, San Francisco, Boston and more. We’ve been virtually high-fiving in our Teams channel throughout the fall as each member picks up ... |
| 18.12.2023 | Biotechs end year 'trading for nothing' as investors mull 'what is IPO-able today?' | “It's been, I would say, probably one of the more challenging years of my professional career.” So says Joel Drewry, a principal investor at Versant Ventures who’s been white-knuckling the rollercoaster ride, or Tower of Terror, that’s been... |
| 18.12.2023 | Alzheimer’s drug approvals show we need a reevaluation of patient advocacy | When faced with a loved one’s progressive neurodegenerative disease, like Alzheimer’s, or your child’s rare respiratory disease, you question why researchers and resource-backed pharma cannot bring a drug to market quickly enough to help yo... |
| 08.12.2023 | Intrigued by Novartis and Lilly deals, investors pour money into radiopharmaceuticals | All of a sudden, radiopharmaceuticals are the hottest game in town—outside of antibody drug conjugates, of course. GlobalData reports that venture capital deals in the space have grown 550% to $408 million this year.
This compares to $63 mi... |
| 08.12.2023 | CORRECTION: Newsletter December 2023 – Summing up the year with a Christmas message and Cline’s bright view of the future | CORRECTION: Newsletter December 2023 – Summing up the year with a Christmas message and Cline’s bright view of the future
Fri, Dec 08, 2023 12:00 CET Report this content
In our Newsletter published on 7TH December 2023, a section was includ... |
| 07.12.2023 | Newsletter December 2023 – Summing up the year with a Christmas message and Cline’s bright view of the future | Newsletter December 2023 – Summing up the year with a Christmas message and Cline’s bright view of the future
Thu, Dec 07, 2023 13:03 CET Report this content
“Dear investors,
Since this past summer, Cline has been in a state of constant cha... |
| 07.12.2023 | Diabetes ‘epidemic’ gets a Senate hearing | You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. March-in mania
The White House today ... |
| 04.12.2023 | Novartis is building a new radioligand plant in China | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya. Today, we explore how traditionally underserved sickle cell patients became early recipients of a futuristic g... |
| 20.11.2023 | Fosun, Treehill launch joint investment business to fund drugs angling for US market | A new collaboration between Fosun Pharma’s U.S. branch and consulting firm Treehill Partners will provide additional resources to help businesses survive the biotech winter.
The two companies have formed a “jointly operating vehicle” to inv... |
| 20.11.2023 | The Disconnect between R&D Costs and High Drug Prices | In the U.S., we pay approximately 2.5 times more than people in other countries. This matters, and it hurts; as much as one in four Americans cannot afford their medication. Unfortunately, the problem of affordability is getting worse. A 20... |
| 20.11.2023 | Merck cough drug doesn’t pass panel scrutiny | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s li... |
| 14.11.2023 | Russell Wilson and Ciara: How the Broncos quarterback and R&B artist make and spend their millions | Entertainment Russell Wilson and Ciara: How the Broncos quarterback and R&B artist make and spend their millions
Meredith Cash
2023-11-13T22:29:48Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Em... |
| 02.11.2023 | Do celebrity vaccine endorsements like Travis Kelce’s actually change behavior? | Once the domain of aging TV stars, hawking health products from vitamins to diabetes supplies to a geriatric demographic, A-list celebrity endorsements of health care products are positively trendy. Migraine sufferer Lady Gaga has a deal wi... |
| 31.10.2023 | Health | Analysis: A new era of vaccines leaves old questions about prices unanswered | Elisabeth Rosenthal | (TNS) KFF Health News
The world is entering a new era of vaccines. Following the success of COVID-19 mRNA shots, scientists have a far greater capacity to tailor shots to a virus’s structure, putting a host of new vacc... |
| 14.10.2023 | Inflation Reduction Act’s Drug Pricing Provisions May Lead To Lower Prices In Oncology | The high price of cancer drugs has led to usage of the term "financial toxicity" to describe the ... [+] cost burden on patients. Even where there are multiple competitors in an class of oncology medicines, branded (and some gener... |
| 09.10.2023 | After pandemic sugar rush, a market 'hangover' opens biotech to funding approaches steeped in stigma | You're not going to hear a private biotech trumpeting a down round as they announce a new batch of funding, but industry experts say the broader market trend has seeped into the sector, while financings as a whole fell 24% last year.
That's... |
| 06.10.2023 | Flush with Wegovy cash, Novo Nordisk's owner widens investment strategy beyond biotech | Outside of a global pandemic, it’s rare for a medicine to truly become a household name. But Novo Nordisk’s Wegovy is rapidly reaching that status, with the obesity drug accruing more front pages and celebrity endorsers every day.
The succe... |
| 05.10.2023 | Ketamine-Based Nasal Spray Can Be a Better Option for Patients With Depression, Clinical Trial Finds | Joseph Henry, Tech Times 05 October 2023, 12:10 pm
(Photo: Kelly Sikkema from Unsplash) Taking ketamine spray along with other antidepressants is found to be more effective than taking an antipsychotic, a new research reveals.
A ketamine-ba... |
| 22.09.2023 | Health | Save billions or stick with Humira? Drug brokers steer Americans to the costly choice | Arthur Allen | (TNS) KFF Health News
Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So when ... |
| 13.09.2023 | Sanofi, Ice-T Unveil Horror-Themed Flu Warning Campaign to Educate Older Adults About Vaccines | John Lopez, Tech Times 13 September 2023, 02:09 pm
Global healthcare company Sanofi has joined forces with rapper and actor Ice-T to launch a groundbreaking flu vaccine campaign, Fierce Pharma tells us in a report.
Titled "The Season,&... |
| 06.09.2023 | Politicians Are At War With The Pharma Industry. And Patient-Consumers Will Be The Losers | WASHINGTON DC, UNITED STATES - AUGUST 29: US President Joe Biden speaks during an event celebrating ... [+] the lowering of drug pricing in the East Room of the White House. (Photo by Nathan Posner/Anadolu Agency via Getty Images)Anadolu Ag... |
| 05.09.2023 | Kim Kardashian’s Promotion Of Full-Body Scans Raises Questions About Social Media Influence In Healthcare | HOLLYWOOD, CALIFORNIA: Kim Kardashian speaks onstage during the 2nd Annual American Influencer ... [+] Awards at Dolby Theatre on November 18, 2019 in Hollywood, California. Recently, Kardashian has been promoting full-body MRI scans on her... |
